Eton Pharmaceuticals, Inc. (ETON) Return on equity 2019–2025
Eton Pharmaceuticals, Inc. (ETON) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.6%FY2025 · since FY2019: -173.6% → -17.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -17.6% | -1.9 pp |
| FY2024 | -15.7% | -9.6 pp |
| FY2023 | -6.0% | +62.9 pp |
| FY2022 | -69.0% | -57.9 pp |
| FY2021 | -11.1% | +147.6 pp |
| FY2020 | -158.7% | +15.0 pp |
| FY2019 | -173.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice